FindTrial
Sign In

Effects of antiviral therapy and variation of immune microenvironment in post-hepatectomy patients with hepatitis-B virus-related hepatocellar carcinoma: a prospective-retrospective study

Effects of antiviral therapy and variation of immune microenvironment in post-hepatectomy patients with hepatitis-B virus-related hepatocellar carcinoma: a prospective-retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019237
Enrollment
Unknown
Registered
2018-11-01
Start date
2018-12-22
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV related HCC

Interventions

Case series:antiviral therapy

Sponsors

the First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with hepatocellular carcinoma associated with hepatitis b received surgical treatment, no liver failure, and no other treatment such as TACE

Exclusion criteria

Exclusion criteria: All patients were excluded from hepatitis c virus infection, drug, autoimmune, schistosomiasis, metabolic and other causes of liver cirrhosis.Other tumors and liver metastases;Hepatic space-occupying lesions were undiagnosed as HCC cases.

Design outcomes

Primary

MeasureTime frame
liver function;—

Countries

China

Contacts

Public ContactXu Xiao

the First Affiliated Hospital of Zhejiang University School of Medicine

zjxu@zju.edu.cn+86 13588191177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026